Transition From Epoprostenol and Treprostinil to the Oral Endothelin Receptor Antagonist Bosentan in Patients With Pulmonary Hypertension
Authors:
- Adaani E. FrostAFAdaani E. Frost
- 1 September 2004
- Vol. 126 (3) , 808-815
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- ATS Statement: Guidelines for the Six-Minute Walk TestAmerican Journal of Respiratory and Critical Care Medicine, 2002
- Bosentan Therapy for Pulmonary Arterial HypertensionNew England Journal of Medicine, 2002
- Recommendations for quantification of Doppler echocardiography: A report from the Doppler quantification task force of the nomenclature and standards committee of the American Society of EchocardiographyJournal of the American Society of Echocardiography, 2002
- Flolan Infusion Interruption: A Lethal Complication during Venous AccessJournal of Vascular and Interventional Radiology, 2001
- Epoprostenol (Prostacyclin) and Pulmonary HypertensionAnnals of Internal Medicine, 2000
- Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of DiseaseAnnals of Internal Medicine, 2000
- Clinical Correlates and Prognostic Significance of Six-minute Walk Test in Patients with Primary Pulmonary Hypertension: Comparison with Cardiopulmonary Exercise TestingAmerican Journal of Respiratory and Critical Care Medicine, 2000
- Infectious complications among patients receiving home intravenous therapy with peripheral, central, or peripherally placed central venous cathetersThe American Journal of Medicine, 1991
- Survival in Patients with Primary Pulmonary HypertensionAnnals of Internal Medicine, 1991
- Recommendations for Quantitation of the Left Ventricle by Two-Dimensional EchocardiographyJournal of the American Society of Echocardiography, 1989